On 24 April 2015, orphan designation (EU/3/15/1473) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for lenalidomide for the treatment of marginal zone lymphoma.
The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in July 2018.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2019 on request of the Sponsor.
|Disease / condition||
Treatment of marginal zone lymphoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;